Saturday, March 17, 2012

Nanopills release drugs directly from the inside of cells

Nanopills release drugs directly from the inside of cells [ Back to EurekAlert! ] Public release date: 16-Mar-2012
[ | E-mail | Share Share ]

Contact: Antoni Villaverde
antoni.villaverde@uab.cat
34-935-813-086
Universitat Autonoma de Barcelona

UAB researchers developed a new vehicle to release proteins with therapeutic effects. The vehicles are known as "bacteria inclusion bodies", stable insoluble nanoparticles which are found normally in recombinant bacteria. Even though these inclusion bodies traditionally have been an obstacle in the industrial production of soluble enzymes and biodrugs, they were recently recognised to have large amounts of functional proteins with direct values in industrial and biomedical applications.

The research team led by Antoni Villaverde from the Institute of Biotechnology and Biomedicine (IBB) at UAB worked in collaboration with the spanish Centro de Investigacin Biomdica en Red en Bioingeniera, Biomateriales y Nanomedicina (CIBER-BBN) to verify the value of these nanoparticles as natural "nanopills" with a strong capacity to penetrate cells and carry out biological activities. The nanopill concept represents a new and promising platform for drug administration and illustrates the yet to be explored power of microbial materials in medicine.

The researchers, in a multidisciplinary study at UAB led by Dr Esther Vzquez, packaged four proteins containing different therapeutic effects into experimental nanopills, the inclusion bodies of the bacteria Escherichia coli. They put the bacteria in contact with cell cultures of mammals under similar conditions to those found in real clinical pathologies, "sick" cells with low viability, and achieved to recover their activity.

Once the technology was licensed to Janus Developments, the tolerance of its administration in vivo was confirmed through experiments conducted by UAB researcher Ester Fernndez. The results and detailed description of the "nanopill" were published in the last issue of the journal Advanced Materials.

The multidisciplinary study included researchers from IBB, the UAB Departments of Genetics and Microbiology and of Cell Biology, Physiology and Immunology, the CIBER-BBN, the CIBER-EHD (Centro de Investigacin Biomdica en Red en el rea temtica de Enfermedades hepticas y Digestivas), the firm Janus Developments, the Leibniz University of Hannover and the Helmholtz Centre for Infection Research in Germany.

The use of inclusion bodies as therapeutic agents was patented by UAB and CIBER-BBN (patent code: WO2010131117A1), and licensed to the biotechnology firm Janus Developments, which currently invests in the development of the product.

###


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Nanopills release drugs directly from the inside of cells [ Back to EurekAlert! ] Public release date: 16-Mar-2012
[ | E-mail | Share Share ]

Contact: Antoni Villaverde
antoni.villaverde@uab.cat
34-935-813-086
Universitat Autonoma de Barcelona

UAB researchers developed a new vehicle to release proteins with therapeutic effects. The vehicles are known as "bacteria inclusion bodies", stable insoluble nanoparticles which are found normally in recombinant bacteria. Even though these inclusion bodies traditionally have been an obstacle in the industrial production of soluble enzymes and biodrugs, they were recently recognised to have large amounts of functional proteins with direct values in industrial and biomedical applications.

The research team led by Antoni Villaverde from the Institute of Biotechnology and Biomedicine (IBB) at UAB worked in collaboration with the spanish Centro de Investigacin Biomdica en Red en Bioingeniera, Biomateriales y Nanomedicina (CIBER-BBN) to verify the value of these nanoparticles as natural "nanopills" with a strong capacity to penetrate cells and carry out biological activities. The nanopill concept represents a new and promising platform for drug administration and illustrates the yet to be explored power of microbial materials in medicine.

The researchers, in a multidisciplinary study at UAB led by Dr Esther Vzquez, packaged four proteins containing different therapeutic effects into experimental nanopills, the inclusion bodies of the bacteria Escherichia coli. They put the bacteria in contact with cell cultures of mammals under similar conditions to those found in real clinical pathologies, "sick" cells with low viability, and achieved to recover their activity.

Once the technology was licensed to Janus Developments, the tolerance of its administration in vivo was confirmed through experiments conducted by UAB researcher Ester Fernndez. The results and detailed description of the "nanopill" were published in the last issue of the journal Advanced Materials.

The multidisciplinary study included researchers from IBB, the UAB Departments of Genetics and Microbiology and of Cell Biology, Physiology and Immunology, the CIBER-BBN, the CIBER-EHD (Centro de Investigacin Biomdica en Red en el rea temtica de Enfermedades hepticas y Digestivas), the firm Janus Developments, the Leibniz University of Hannover and the Helmholtz Centre for Infection Research in Germany.

The use of inclusion bodies as therapeutic agents was patented by UAB and CIBER-BBN (patent code: WO2010131117A1), and licensed to the biotechnology firm Janus Developments, which currently invests in the development of the product.

###


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Source: http://www.eurekalert.org/pub_releases/2012-03/uadb-nrd031612.php

mike mcqueary joe paterno fired joe paterno fired matt nathanson matt nathanson rick perry oops rick perry oops

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.